U.S. Food and Drug Administration (FDA) has approved Afrezza Inhalation Powder for use in children and adolescents aged 6 and ...

MannKind Corporation (NASDAQ:MNKD) is among the best fundamentally strong penny stocks to invest in now. On April 8, TheFly reported that Truist trimmed the price target on MannKind Corporation ...

A major catalyst window opens for this biopharma stock with Q1 earnings due on May 6, and two key FDA decisions in May and July.

MannKind (NASDAQ: MNKD) was a stock to avoid on the second-to-last trading day of the week. Investors eagerly sold out of the commercial-stage biotech's equity, as they clearly felt its latest ...

View MannKind Corporation MNKD stock quote prices, financial information, real-time forecasts, and company news from CNN.

Transaction value based on SEC Form 4 weighted average purchase price ($6.01); post-transaction value based on Dec. 17, 2025 market close price ($5.97). MannKind Corporation is a biotechnology company ...

・MannKind’s stock has gained momentum amid optimism over its expanding diabetes portfolio and 2026 milestones. ・CEO Michael Castagna said the FDA has accepted its Afrezza pediatric application, ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. MannKind (MNKD) is a stock that can certainly grab the attention ...

CEO Michael Castagna sold 65,804 shares on Dec. 17, 2025, for a total value of approximately ~$395,482 at a weighted average price around $6.01 per share. This transaction represented 2.56% of Mr.